Open medicine : a peer-reviewed, independent, open-access journal最新文献

{"title":"A vision for cannabis regulation: a public health approach based on lessons learned from the regulation of alcohol and tobacco.","authors":"Mark Haden, Brian Emerson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"8 2","pages":"e73-80"},"PeriodicalIF":0.0,"publicationDate":"2014-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/49/67/OpenMed-08-73.PMC4085088.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32493055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A clinician's guide to the assessment and interpretation of noninferiority trials for novel therapies.","authors":"Simon J W Oczkowski","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A noninferiority trial is designed to demonstrate that an experimental therapy is not worse than an active control. Although noninferiority trials are superficially similar to conventional superiority trials, there are fundamental differences. In particular, aspects of a study that make the therapies appear more similar than they actually are can falsely bias the study toward demonstrating noninferiority. This has important implications for methodologic techniques such as blinding and statistical analysis based on the intention-to-treat principle. When applying the results of noninferiority trials, clinicians should be judicious in determining whether the degree of noninferiority demonstrated is clinically acceptable and whether the ancillary benefits of the treatment justify its use. </p>","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"8 2","pages":"e67-72"},"PeriodicalIF":0.0,"publicationDate":"2014-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/b5/OpenMed-08-67.PMC4085087.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32493053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision-making about complementary and alternative medicine by cancer patients: integrative literature review.","authors":"Laura Weeks,&nbsp;Lynda G Balneaves,&nbsp;Charlotte Paterson,&nbsp;Marja Verhoef","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Patients with cancer consistently report conflict and anxiety when making decisions about complementary and alternative medicine (CAM) treatment. To design evidence-informed decision-support strategies, a better understanding is needed of how the decision-making process unfolds for these patients during their experience with cancer. We undertook this study to review the research literature regarding CAM-related decision-making by patients with cancer within the context of treatment, survivorship, and palliation. We also aimed to summarize emergent concepts within a preliminary conceptual framework.</p><p><strong>Methods: </strong>We conducted an integrative literature review, searching 12 electronic databases for articles published in English that described studies of the process, context, or outcomes of CAM-related decision-making. We summarized descriptive data using frequencies and used a descriptive constant comparative method to analyze statements about original qualitative results, with the goal of identifying distinct concepts pertaining to CAM-related decision-making by patients with cancer and the relationships among these concepts.</p><p><strong>Results: </strong>Of 425 articles initially identified, 35 met our inclusion criteria. Seven unique concepts related to CAM and cancer decision-making emerged: decision-making phases, information-seeking and evaluation, decision-making roles, beliefs, contextual factors, decision-making outcomes, and the relationship between CAM and conventional medical decision-making. CAM decision-making begins with the diagnosis of cancer and encompasses 3 distinct phases (early, mid, and late), each marked by unique aims for CAM treatment and distinct patterns of information-seeking and evaluation. Phase transitions correspond to changes in health status or other milestones within the cancer trajectory. An emergent conceptual framework illustrating relationships among the 7 central concepts is presented.</p><p><strong>Interpretation: </strong>CAM-related decision-making by patients with cancer occurs as a nonlinear, complex, dynamic process. The conceptual framework presented here identifies influential factors within that process, as well as patients' unique needs during different phases. The framework can guide the development and evaluation of theory-based decision-support programs that are responsive to patients' beliefs and preferences.</p>","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"8 2","pages":"e54-66"},"PeriodicalIF":0.0,"publicationDate":"2014-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/9d/OpenMed-08-54.PMC4085086.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32493054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health system capacity and infrastructure for adopting innovations to care for patients with venous thromboembolic disease.","authors":"Danielle A Southern,&nbsp;Jasmine Poole,&nbsp;Alka Patel,&nbsp;Nigel Waters,&nbsp;Louise Pilote,&nbsp;Russell D Hull,&nbsp;William A Ghali","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Diagnosis and treatment for venous thromboembolic disease (VTE) have evolved considerably through diagnostic and therapeutic innovations. Despite their considerable potential for enhancing care, however, the extent to which these innovations are being adopted in usual practice is unknown. We documented the infrastructure available in hospitals and health regions across Canada for provision of optimal diagnosis and therapy for VTE disease.</p><p><strong>Methods: </strong>Over the period January 2008 through October 2009, we studied health system infrastructure for care of VTE disease in Canada's 10 provinces and 3 territories and all 94 health regions therein. We interviewed health system managers and/or clinical leaders from all 658 acute care hospitals in Canada and documented key elements of health system infrastructure at the hospital level for these institutions.</p><p><strong>Results: </strong>There was considerable variation across Canada in the availability of key infrastructure for the diagnosis and management of VTE disease. Provinces with higher populations tended to have a large proportion of hospitals with capability to measure d-dimer levels, whereas less populated provinces were more likely to send samples to centralized analysis facilities for d-dimer testing. All provinces and territories had some facilities offering advanced diagnostic imaging, but the number of institutions and the availability of imaging were highly variable (with the proportion offering at least limited availability ranging from 0% to 90%). Only 6 provinces had regions with availability of dedicated early and/or long-term outpatient clinics for VTE disease.</p><p><strong>Conclusions: </strong>Infrastructure in Canada for optimal care of patients with VTE disease was suboptimal during the study period and was not entirely in step with the evidence. Such shortfalls in health system infrastructure limit the extent to which health care providers can deliver optimal, evidence-based care to their patients. Nationwide evaluations of health system infrastructure such as this one should be undertaken internationally to better characterize quality of care and potential for improvement.</p>","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"8 2","pages":"e46-53"},"PeriodicalIF":0.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/20/OpenMed-08-46.PMC4085085.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32492588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High rates of hospital admission among older residents in assisted living facilities: opportunities for intervention and impact on acute care.","authors":"David B Hogan,&nbsp;Joseph E Amuah,&nbsp;Laurel A Strain,&nbsp;Walter P Wodchis,&nbsp;Andrea Soo,&nbsp;Misha Eliasziw,&nbsp;Andrea Gruneir,&nbsp;Brad Hagen,&nbsp;Gary Teare,&nbsp;Colleen J Maxwell","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Little is known about health or service use outcomes for residents of Canadian assisted living facilities. Our objectives were to estimate the incidence of admission to hospital over 1 year for residents of designated (i.e., publicly funded) assisted living (DAL) facilities in Alberta, to compare this rate with the rate among residents of long-term care facilities, and to identify individual and facility predictors of hospital admission for DAL residents.</p><p><strong>Methods: </strong>Participants were 1066 DAL residents (mean age ± standard deviation 84.9 ± 7.3 years) and 976 longterm care residents (85.4 ± 7.6 years) from the Alberta Continuing Care Epidemiological Studies (ACCES). Research nurses completed a standardized comprehensive assessment for each resident and interviewed family caregivers at baseline (2006 to 2008) and 1 year later. We used standardized interviews with administrators to generate facility- level data. We determined hospital admissions through linkage with the Alberta Inpatient Discharge Abstract Database. We used multivariable Cox proportional hazards models to identify predictors of hospital admission.</p><p><strong>Results: </strong>The cumulative annual incidence of hospital admission was 38.9% (95% confidence interval [CI] 35.9%- 41.9%) for DAL residents and 13.7% (95% CI 11.5%-15.8%) for long-term care residents. The risk of hospital admission was significantly greater for DAL residents with greater health instability, fatigue, medication use (11 or more medications), and 2 or more hospital admissions in the preceding year. The risk of hospital admission was also significantly higher for residents from DAL facilities with a smaller number of spaces, no licensed practical and/ or registered nurses on site (or on site less than 24 hours a day, 7 days a week), no chain affiliation, and from select health regions.</p><p><strong>Interpretation: </strong>The incidence of hospital admission was about 3 times higher among DAL residents than among long-term care residents, and the risk of hospital admission was associated with a number of potentially modifiable factors. These findings raise questions about the complement of services and staffing required within assisted living facilities and the potential impact on acute care of the shift from long-term care to assisted living for the facility-based care of vulnerable older people.</p>","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"8 1","pages":"e33-45"},"PeriodicalIF":0.0,"publicationDate":"2014-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/75/OpenMed-08-33.PMC4085093.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32491571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Travel-acquired infections and illnesses in Canadians: surveillance report from CanTravNet surveillance data, 2009-2011.","authors":"Andrea K Boggild, Jennifer Geduld, Michael Libman, Brian J Ward, Anne E McCarthy, Patrick W Doyle, Wayne Ghesquiere, Jean Vincelette, Susan Kuhn, David O Freedman, Kevin C Kain","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Important knowledge gaps exist in our understanding of migration medicine practice and the impact of pathogens imported by Canadian travellers. We present here a comprehensive, Canada-specific surveillance summary of illness in a cohort of returned Canadian travellers and new immigrants.</p><p><strong>Methods: </strong>We extracted and analyzed (using standard parametric and nonparametric techniques) data from the Canadian Travel Medicine Network (CanTravNet) database for ill returned Canadian travellers and new immigrants who presented to a Canadian GeoSentinel Surveillance Network site between September 2009 and September 2011.</p><p><strong>Results: </strong>During the study period, 4365 travellers and immigrants presented to a CanTravNet site, 3943 (90.3%) of whom were assigned a travel-related diagnosis. Among the 3115 non-immigrant travellers with a definitive travel-related diagnosis, arthropod bite (n = 127 [4.1%]), giardiasis (n = 91 [2.9%]), malaria (n = 77 [2.5%]), latent tuberculosis (n = 73 [2.3%]), and strongyloidiasis (n = 66 [2.1%]) were the most common specific etiologic diagnoses. Among the 828 immigrants with definitive travel-related diagnoses, the most frequent etiologies were latent tuberculosis (n = 229 [27.7%]), chronic hepatitis B (n = 182 [22.0%]), active tuberculosis (n = 97 [11.7%]), chronic hepatitis C (n = 89 [10.7%]), and strongyloidiasis (n = 41 [5.0%]). Potentially serious infections, such as dengue fever (61 cases) and enteric fever due to Salmonella enterica serotype Typhi or Paratyphi (36 cases), were common. Individuals travelling for the purpose of visiting friends and relatives (n = 500 [11.6% of those with known reason for travel]) were over-represented among those diagnosed with malaria and enteric fever, compared with other illnesses (for malaria 34/94 [36.2%] v. 466/4221 [11.0%]; for enteric fever, 17/36 [47.2%] v. 483/4279 [11.3%]) (both p < 0.001). For cases of malaria, there was also overrepresentation (compared with other illnesses) from business travellers (22/94 [23.4%] v. 337/4221 [8.0%]) and males (62/94 [66.0%] v. 1964/4269 [46.0%]) (both p < 0.001). Malaria was more likely than other illnesses to be acquired in sub-Saharan Africa (p < 0.001), whereas dengue was more likely than other illnesses to be imported from the Caribbean and South East Asia (both p = 0.003) and enteric fever from South Central Asia (24/36 [66.7%]) (p < 0.001).</p><p><strong>Interpretation: </strong>This analysis of surveillance data on ill returned Canadian travellers has detailed the spectrum of imported illness within this cohort. It provides an epidemiologic framework for Canadian practitioners encountering ill returned travellers. We have confirmed that travel to visit friends and relatives confers particularly high risks, which underscores the need to improve pretravel intervention for a population that is unlikely to seek specific pretravel advice. Potentially serious and fatal illnes","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"8 1","pages":"e20-32"},"PeriodicalIF":0.0,"publicationDate":"2014-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/96/OpenMed-08-20.PMC4085092.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32491570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009.","authors":"Joel Lexchin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Studying drugs withdrawn from the market for safety reasons can help in evaluating the strengths and weaknesses of the pre- and post-market safety evaluation systems. This study considered 2 questions: Has there been a change over time in the percentage of new drugs that are eventually withdrawn because of safety reasons? How long are new drugs on the market before their serious safety problems are recognized?</p><p><strong>Methods: </strong>All drugs approved between 1 January 1990 and 31 December 2009 and subsequently withdrawn for safety reasons (until 1 October 2013) were identified, and the generic name, date of approval, and date of withdrawal were recorded. The total number of drugs approved over the same period was obtained from annual Health Canada reports. The percentages of new active substances approved in the 5-year periods 1990-1994, 1995-1999, 2000-2004, and 2005-2009 and eventually withdrawn were compared using the χ(2) test. The time between approval and withdrawal was calculated in days.</p><p><strong>Results: </strong>Of the 528 new drugs approved over the period of interest, a total of 22 (4.2%) were eventually withdrawn. Between 3.9% and 4.4% of the drugs approved in each 5-year period were eventually withdrawn (χ(2) = 0.04, p = 0.99 for difference among 5-year periods). The median time between approval and withdrawal was 1271 days (interquartile range 706-2876).</p><p><strong>Interpretation: </strong>One explanation for the finding of no difference in the percentage of drugs approved in the four 5-year periods that were eventually withdrawn is the lack of any change in the rigour of the premarket evaluation system and the postmarket surveillance systems. The 1271-day median time between Notice of Compliance and withdrawal emphasizes the need to be particularly cautious in prescribing new drugs early in their life cycle.</p>","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"8 1","pages":"e14-9"},"PeriodicalIF":0.0,"publicationDate":"2014-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/40/OpenMed-08-14.PMC4085091.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32491569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Sunshine Act: commercial conflicts of interest and the limits of transparency.","authors":"Mark Wilson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"8 1","pages":"e10-3"},"PeriodicalIF":0.0,"publicationDate":"2014-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/73/OpenMed-08-10.PMC4085090.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32491568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gestational diabetes and risk of cardiovascular disease: a scoping review.","authors":"Cyril Archambault,&nbsp;Roxane Arel,&nbsp;Kristian B Filion","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus is associated with an increased risk of incident type 2 diabetes and has deleterious effects on other cardiovascular risk factors. However, the effect of gestational diabetes on the risk of cardiovascular disease remains unclear. We conducted a scoping review of the literature to examine the association between these 2 conditions.</p><p><strong>Methods: </strong>We systematically searched the PubMed and Embase databases for studies examining the association between gestational diabetes and cardiovascular disease. We restricted our search to studies involving humans that were published in English or French. Outcomes of interest included acute coronary syndromes, angina, arrhythmia, coronary artery disease, heart failure, myocardial infarction, stroke, and composite end points with these outcomes.</p><p><strong>Results: </strong>A total of 11 publications (3 cohort studies [1 published as an abstract], 2 cross-sectional studies, 1 case-control study [published as an abstract], 4 narrative reviews, and 1 editorial) met our inclusion criteria. The 2 cohort studies published as full manuscripts were conducted in overlapping populations. The included studies reported a range of adjusted relative risks for incident cardiovascular disease, from not significant to 1.85 (95% confidence interval [CI] 1.21 to 2.82). Adjustment for subsequent type 2 diabetes mellitus attenuated the effects but with wide 95% CIs that spanned unity (range 1.13 [95% CI 0.67 to 1.89] to 1.56 [95% CI 1.00 to 2.43]).</p><p><strong>Interpretation: </strong>Available data suggest that gestational diabetes is associated with an increased risk of cardiovascular disease. However, these data are limited, and evidence regarding this association independent of the increased risk due to subsequent type 2 diabetes and other risk factors for cardiovascular disease remains inconclusive.</p>","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"8 1","pages":"e1-9"},"PeriodicalIF":0.0,"publicationDate":"2014-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/af/68/OpenMed-08-01.PMC4085089.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32491567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Federal government food policy committees and the financial interests of the food sector.","authors":"Norm Campbell,&nbsp;Kevin J Willis,&nbsp;Gavin Arthur,&nbsp;Bill Jeffery,&nbsp;Helen Lee Robertson,&nbsp;Diane L Lorenzetti","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":88624,"journal":{"name":"Open medicine : a peer-reviewed, independent, open-access journal","volume":"7 4","pages":"e107-11"},"PeriodicalIF":0.0,"publicationDate":"2013-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/90/OpenMed-07-107.PMC4161498.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32680642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}